Alecto's creative writing o' the day...

April 16, 2048
WASHINGTON --- Rep. Oliviah Carlisle (G-CA) announced last night that she would be bringing a new piece of legislation before Congress that would streamline the procedure for delivering state financial assistance to sufferers of Chronic Leuprorelin-Induced Wasting Syndrome (CLIWS), a multi-system health disorder that attacks the bones, muscles, reproductive organs, and brain of those who were administered the drug leuprorelin (once sold under the trade name Luprod by the company Cabot Laboratories, and by other names by other companies) during the Gender Panic of the first third of the century. Many CLIWS sufferers also suffer from Leuprorelin-Induced Developmental Disorder (LIDD), a learning disorder stemming from total pubertal disruption that leaves them with an approximately ten-point deficit in IQ, which, once believed to be minor, upon long-term followup, has been correlated with significant reductions in educational attainment, job security and productivity, and income potential which, when combined with CLIWS symptoms, makes them particularly vulnerable.

CLIWS patients, often called subadults due to their failure to reach sexual maturity, were administered the prostate cancer drug -- which had never been tested in children -- for several years, before being given either synthetic testosterone (for girls) or synthetic estrogen (for boys). By 2022, children were receiving leuprorelin as young as eight years old in hundreds of gender clinics, offline and online, across North America, Britannia, Europe, and Australia. Scientists began studying the effects of combining early-age leuprorelin administration with wrong-sex hormones in 2028, but struggled to publish their results in English, as over sixty medical journals faced legal and sociomedial attacks if they did. Finally in 2034, under increasing pressure from members after a catastrophic nurses’ strike, the American Medical Association released a guidance paper in which they recommended that genderologists, family doctors, pediatricians, endocrinologists, and physician’s assistants tasked with treating gender patients test their pediatric and ex-pediatric patients for bone loss, muscle wasting, cardiovascular defects, neurological deficiencies, developmental retardation, sexual dysfunction, and infertility.

Over the course of the next several years, as more than 180,000 leuprorelin patients were diagnosed with what would later be described as CLIWS in the medical literature, the FDA issued a recall of leuprorelin and related drugs, after unsuccessfully attempting to stem their illegal sale.

[To read the whole article, click here: https://justpaste.it/april162048 ]